Premium
In Vitro Studies of Fe 3 O 4 ‐ZIF‐8 Core–Shell Nanoparticles Designed as Potential Theragnostics
Author(s) -
Ettlinger Romy,
Moreno Natalia,
Ziółkowska Natalia,
Ullrich Aladin,
Krug von Nidda HansAlbrecht,
Jirák Daniel,
Kerl Kornelius,
Bunzen Hana
Publication year - 2020
Publication title -
particle and particle systems characterization
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.877
H-Index - 56
eISSN - 1521-4117
pISSN - 0934-0866
DOI - 10.1002/ppsc.202000185
Subject(s) - zeolitic imidazolate framework , nanoparticle , chemistry , nanotechnology , nuclear chemistry , imidazolate , in vitro , materials science , metal organic framework , organic chemistry , biochemistry , adsorption
Theragnostics represent a combination of therapy and diagnosis within one system. Herein, Fe 3 O 4 ‐ZIF‐8 core–shell nanoparticles are developed and suggested as candidates for theragnostic applications in cancer treatment. A drug loaded metal–organic framework ZIF‐8 (zeolitic imidazolate framework‐8) represents the therapeutic tool, while the Fe 3 O 4 core is included to enable the material visualization by magnetic resonance imaging (MRI). A reliable synthesis of Fe 3 O 4 ‐ZIF‐8 core–shell nanoparticles of an average size below 100 nm is reported. The nanoparticles are characterized by FT‐IR, TGA, XRPD, TEM, STEM‐EDS, DLS, ICP‐OES, CHN‐elemental analysis, SQUID measurements, and MRI. Moreover, their chemical stability and in vitro cytotoxicity against fibroblast and selected cancer cell lines are evaluated. As a model drug, arsenic trioxide—a promising anticancer drug—is used. The drug release can be triggered by a pH change from 7.4 to 6.0 and the nanoparticles can be visualized by MRI in vitro, thus a potential theragnostic agent for cancer treatment is developed.